Welcome to our dedicated page for Innoviva SEC filings (Ticker: INVA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Innoviva, Inc. (NASDAQ: INVA) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures, including Forms 10-K, 10-Q, 8-K, and other documents filed with the U.S. Securities and Exchange Commission. Innoviva is a diversified healthcare holding company with a royalties portfolio linked to GSK respiratory products, a critical care and infectious disease platform operated through Innoviva Specialty Therapeutics, and a portfolio of strategic healthcare investments.
In its SEC reports, Innoviva discusses royalty revenue from RELVAR®/BREO® ELLIPTA® and ANORO® ELLIPTA®, net product sales from therapies such as GIAPREZA®, XERAVA®, XACDURO®, and ZEVTERA®, and the performance of its strategic investment portfolio. Current reports on Form 8-K, for example, furnish quarterly earnings press releases that detail revenue composition, income from operations, changes in fair values of equity and long-term investments, and balance sheet metrics.
For investors following Innoviva’s infectious disease and critical care focus, periodic filings also provide context on regulatory milestones and development programs, such as the New Drug Application for zoliflodacin and its QIDP designation. Proxy statements and related documents can offer additional insight into governance, equity compensation, and capital allocation policies, while registration statements and prospectuses may describe financing activities.
On Stock Titan, each Innoviva filing is accompanied by AI-powered summaries designed to highlight key points, such as changes in royalty streams, trends in IST net product sales, significant investments or licensing transactions, and updates to risk factors. Users can quickly scan recent 10-Q and 10-K reports, review 8-K announcements, and examine Form 4 insider transaction filings to understand how executives and directors are trading INVA shares. Real-time integration with EDGAR helps ensure that new Innoviva filings appear promptly, while AI-generated overviews make dense regulatory documents more accessible to both individual and professional investors.
Innoviva, Inc. (INVA) reported insider equity activity. The reporting person acquired 110,436 shares of common stock at $18.11 on November 3, 2025, noted as a time‑vested RSU grant. 25% vests on November 20, 2026, with the remainder vesting in 12 substantially equal quarterly installments, subject to continuous service, with accelerated vesting upon specified change‑in‑control conditions.
The filing also shows 1,860 shares acquired at $0 under the Employee Stock Purchase Plan on May 15, 2025. Following the reported transactions, the reporting person beneficially owned 162,276 shares directly.
Innoviva, Inc. reported stronger Q3 2025 results. Total revenue for the three months ended September 30, 2025 was $107.8 million, up from $89.5 million a year ago, driven by $59.9 million in royalty revenue and $47.3 million in net product sales. Net income rose to $89.9 million (diluted EPS $1.08) from $1.2 million (diluted EPS $0.02) in Q3 2024, aided by gains in the fair values of investments.
Year-to-date through Q3 2025, revenue reached $296.7 million with net income of $107.0 million. Cash and cash equivalents were $476.5 million as of September 30, 2025, supported by $142.4 million in operating cash flow for the nine-month period. The company eliminated its current balance on the 2025 convertible notes through conversions totaling $192.5 million to common stock, while long-term debt stood at $257.4 million. Common shares outstanding were 74,769,062 as of October 31, 2025.
Innoviva, Inc. (INVA) furnished an 8-K announcing its quarterly results press release. On November 5, 2025, the company provided a press release covering results for the quarter ended September 30, 2025, attached as Exhibit 99.1. The disclosure under Item 2.02 is furnished, not filed, and is not subject to Section 18 liabilities, nor incorporated by reference unless specifically stated.
Bank of Nova Scotia filed an amended Schedule 13G reporting beneficial ownership of 2,179,005 shares of Innoviva, Inc. common stock, representing
Bank of Nova Scotia reported ownership of 3,585,830 shares of Innoviva, Inc. common stock, representing 5.55% of the class, on a Schedule 13G/A filing. The bank identifies itself as a parent holding company organized in Canada and states the shares are held in the ordinary course of business and not for the purpose of changing or influencing control of Innoviva. The filing lists sole voting and dispositive power over the reported shares and supplies Innoviva's principal executive office address.
Insider sale via tax-withholding reduced holdings. Innoviva CFO Stephen Basso reported a disposition of 237 shares of Common Stock on 08/20/2025 at a reported price of $19.95 per share. The filing states the shares were withheld by the issuer to satisfy income tax withholding obligations tied to the quarterly vesting of previously granted employee equity awards. After the transaction Mr. Basso beneficially owned 23,281 shares directly. The form is signed and dated 08/22/2025.
Marianne Zhen, Chief Accounting Officer of Innoviva, Inc. (INVA), reported a disposition of company stock on 08/20/2025. The Form 4 shows 991 shares were disposed at a price of $19.95 per share, leaving 49,329 shares beneficially owned after the transaction. The filing explains the shares were withheld by the issuer to satisfy income tax withholding related to the quarterly vesting of previously granted employee equity awards.
Renaissance Technologies LLC and Renaissance Technologies Holdings Corporation report beneficial ownership of 4,760,832 shares of Innoviva, Inc. common stock (CUSIP 45781M101), representing 7.56% of the outstanding class. The filing shows the reporting persons have sole voting and sole dispositive power over these shares. The statement is made on a Schedule 13G/A and includes a certification that the shares are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer. Certain funds managed by Renaissance may have rights to dividends or sale proceeds related to these securities.